US EditionHealth Adds to the SNS the New Treatment of Astrazeneca for HPN
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Astrazeneca has announced that the Ministry of Health has included one of its drugs in the pharmaceutical provision of the National Health System (NSS) as a complementary treatment to ravulizumab or eculizumab for adult patients with nocturnal paroxysmal hemoglobinuria (NPH) who have residual haemolytic anaemia. This decision comes after the approval of treatment by the European Commission in 2024. This 'ok' was based on the results of the pivot…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
